Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part and are able to sign a consent form agreeing to participate
• People aged 18 to 80 years old at the time of signing the consent form
• People who have been diagnosed through a tissue or cell sample with locally advanced (stage IIIB or IIIC), metastatic, or recurrent (stage IV) non-small cell lung cancer (NSCLC) that cannot be treated with surgery or a combination of chemotherapy and radiation aimed at curing the disease
• People who have not previously received any intravenous (drip) cancer treatment, and whose cancer does not have certain specific genetic changes called "driver gene mutations"
• People whose cancer cells show a PD-L1 protein level of less than 50% (a result from a lab test on the tumour)
• People who have at least one tumour that can be measured on a scan, meaning a single lesion of 10mm or more, or an enlarged lymph node of 15mm or more on CT or MRI
• People who have a general health and activity level score of 0 or 1 on a standard medical scale (meaning fully active or restricted only in strenuous activity)
• People whose life expectancy is estimated to be more than 3 months
• People whose blood, liver, kidney, and clotting functions all meet specific levels on tests done within 7 days before joining (without having received corrective treatments such as blood transfusions or growth factors in the 14 days before those tests) (confirm with trial site for exact values)
• People assigned female at birth who are of reproductive age and have a negative pregnancy test within 3 days before the first dose
• People (and their sexual partners) who agree to use approved contraception during treatment and for 6 months after treatment ends

Who may not be able to join:

• People who are currently in another interventional clinical trial, or who have received another experimental drug or device within the 4 weeks before the first dose
• People who have received traditional Chinese medicines with anti-cancer indications, or immune-modifying drugs (such as thymosin, interferon, or interleukin), within 2 weeks before the first dose, or who have had major surgery within 3 weeks before the first dose
• People with severe heart failure (Class III–IV) or poorly controlled, clinically significant irregular heart rhythms
• People who have experienced a heart attack, unstable chest pain, stroke, or mini-stroke within the 6 months before starting treatment
• People with a known allergy to any of the drugs used in this trial
• People who need long-term steroid medicines taken by mouth, drip, or injection on an ongoing basis
• People with brain or nervous system spread of cancer that is causing symptoms — though people with brain metastases that are not causing symptoms, or whose symptoms have stabilised after treatment, may still be considered if they meet additional specific conditions (confirm with trial site)
• People who have an active infection currently being treated, or who have used systemic antibiotics or antifungals in the week before the first dose
• People who have not sufficiently recovered from side effects or complications of any previous treatment before starting this trial (confirm with trial site)
• People with a known history of HIV infection
• People with untreated active hepatitis B, defined by specific blood test results showing active virus (confirm with trial site)
• People with active hepatitis C infection, defined by specific blood test results (confirm with trial site)
• People who have received a live vaccine within 30 days before the first dose — though standard injected inactivated flu vaccines are permitted; nasal spray live flu vaccines are not
• People who are pregnant or breastfeeding
• People with any other medical history, condition, or test result that the trial investigators consider unsuitable for safe participation

Important: Always verify eligibility with the trial site directly before applying.